JP2003531916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003531916A5 JP2003531916A5 JP2001580936A JP2001580936A JP2003531916A5 JP 2003531916 A5 JP2003531916 A5 JP 2003531916A5 JP 2001580936 A JP2001580936 A JP 2001580936A JP 2001580936 A JP2001580936 A JP 2001580936A JP 2003531916 A5 JP2003531916 A5 JP 2003531916A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- carbon
- hydrogen
- compound according
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 69
- 238000000034 method Methods 0.000 description 39
- 229910052799 carbon Inorganic materials 0.000 description 37
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 32
- 229910052739 hydrogen Inorganic materials 0.000 description 29
- 239000001257 hydrogen Substances 0.000 description 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 21
- 125000005842 heteroatom Chemical group 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 11
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 229910052710 silicon Inorganic materials 0.000 description 9
- 239000010703 silicon Chemical group 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 125000005549 heteroarylene group Chemical group 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 229910052717 sulfur Chemical group 0.000 description 7
- 239000011593 sulfur Chemical group 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical group 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 229910052796 boron Inorganic materials 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000004404 heteroalkyl group Chemical group 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 125000000962 organic group Chemical group 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical group [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical group [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 125000006243 carbonyl protecting group Chemical group 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Chemical group 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- QSYIMQZNRNAVEX-LNWOZICCSA-N (8s,9s,10r,13r,14s,17s)-17-ethyl-6,7-dihydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one Chemical group OC1C(O)C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 QSYIMQZNRNAVEX-LNWOZICCSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- CQKNGOYFOHNTQR-DAXIYFSVSA-N CCCNCCNC(CC1)CC([C@H]2O)[C@@]1(C)C(CC[C@@](C)(C1CC3)/C3=C\C)C1[C@H]2O Chemical compound CCCNCCNC(CC1)CC([C@H]2O)[C@@]1(C)C(CC[C@@](C)(C1CC3)/C3=C\C)C1[C@H]2O CQKNGOYFOHNTQR-DAXIYFSVSA-N 0.000 description 1
- FPCOQXANCUIVON-APPYGHHSSA-N C[C@](CCC1[C@@](C)(CCC(C2)NC3CCCCC3)C2[C@H]2O)(C(CC3)C1[C@H]2O)/C3=C\C Chemical compound C[C@](CCC1[C@@](C)(CCC(C2)NC3CCCCC3)C2[C@H]2O)(C(CC3)C1[C@H]2O)/C3=C\C FPCOQXANCUIVON-APPYGHHSSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229910003844 NSO2 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- -1 nitro-substituted phenyl Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20061700P | 2000-04-28 | 2000-04-28 | |
| US60/200,617 | 2000-04-28 | ||
| PCT/CA2001/000581 WO2001083512A1 (en) | 2000-04-28 | 2001-04-30 | 3-nitrogen-6,7-dioxygen steroids and uses related thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003531916A JP2003531916A (ja) | 2003-10-28 |
| JP2003531916A5 true JP2003531916A5 (cg-RX-API-DMAC10.html) | 2008-06-05 |
Family
ID=22742458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001580936A Pending JP2003531916A (ja) | 2000-04-28 | 2001-04-30 | ３−窒素−６，７−二酸素化ステロイドおよびそれに関連した使用 |
Country Status (33)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| SK15692002A3 (sk) * | 2000-04-28 | 2003-11-04 | Inflazyme Pharmaceuticals Limited | 3-Amino-6,7-dioxygénované steroidy a s nimi súvisiace použitie |
| AU2002303425A1 (en) * | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent |
| US6696580B2 (en) | 2001-05-22 | 2004-02-24 | Inflazyme Pharmaceuticals Ltd. | Process for the production of 6,7-diols of steroidal compounds |
| EP1526140B1 (en) * | 2002-08-01 | 2008-11-05 | Astellas Pharma Inc. | Potassium-dependent sodium-calcium exchanger |
| US20050113318A1 (en) * | 2003-07-31 | 2005-05-26 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20090263381A1 (en) * | 2003-07-31 | 2009-10-22 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| US20050101545A1 (en) * | 2003-07-31 | 2005-05-12 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20090285900A1 (en) * | 2003-07-31 | 2009-11-19 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20050043282A1 (en) * | 2003-07-31 | 2005-02-24 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20090317476A1 (en) * | 2003-07-31 | 2009-12-24 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026882A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| US20050038004A1 (en) * | 2003-07-31 | 2005-02-17 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20110209699A1 (en) * | 2003-07-31 | 2011-09-01 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026884A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026879A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026881A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
| US20090297611A1 (en) * | 2003-07-31 | 2009-12-03 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20080051382A1 (en) * | 2003-10-20 | 2008-02-28 | Inflazyme Pharmaceuticals Ltd. | Crystalline Forms of 3-Beta-Amino 17-Methylene Androstane-6-Alpha 7-Beta-Diol Hydrochloride |
| EP1680441A1 (fr) * | 2003-10-20 | 2006-07-19 | Inflazyme Pharmaceuticals, Ltd. | Formes cristallines du chlorhydrate de 3-beta-amino, 17-methylene, androstane-6-alpha, 7-beta-diol |
| FR2861077B1 (fr) * | 2003-10-20 | 2006-03-03 | Aventis Pharma Sa | Formes cristallines du chlorydrate de 3-beta-amino, 17-methylene, androstane-6-alpha, 7-beta-diol |
| US20050222049A1 (en) * | 2004-03-31 | 2005-10-06 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis |
| US20050227927A1 (en) * | 2004-03-31 | 2005-10-13 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis |
| US20090317477A1 (en) * | 2004-03-31 | 2009-12-24 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis |
| AU2008326386B2 (en) * | 2007-11-21 | 2014-07-31 | The Procter & Gamble Company | Preparations, methods and kits useful for treatment of cough |
| JP5655243B2 (ja) * | 2009-10-19 | 2015-01-21 | 国立大学法人 熊本大学 | インドキシル硫酸の産生の阻害剤のスクリーニング方法、インドキシル硫酸代謝産生阻害剤、及び腎障害軽減剤 |
| ES2654584T3 (es) | 2010-01-15 | 2018-02-14 | Suzhou Neupharma Co., Ltd | Ciertas entidades químicas, composiciones y métodos |
| MX375112B (es) | 2010-07-09 | 2025-03-06 | Biogen Hemophilia Inc | Polipéptidos de factor ix y métodos para usarlos. |
| EP3453714B1 (en) | 2011-02-02 | 2020-11-04 | Suzhou Neupharma Co., Ltd | Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof |
| EP3453713B1 (en) * | 2012-04-29 | 2021-09-08 | Neupharma, Inc. | Bufadienolide compounds substituted in position 3 by an amine group for use in the treatment of cancer |
| WO2014052490A1 (en) | 2012-09-25 | 2014-04-03 | Biogen Idec Ma Inc. | Methods of using fix polypeptides |
| EP2970122B1 (en) | 2013-03-14 | 2019-05-08 | Aquinox Pharmaceuticals (Canada) Inc. | Ship1 modulators |
| US10100056B2 (en) | 2013-03-14 | 2018-10-16 | Aquinox Pharmaceuticals (Canada) Inc. | SHIP1 modulators and methods related thereto |
| SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
| CN104744547B (zh) * | 2013-12-27 | 2017-02-15 | 天津医科大学 | 一种抗乳腺癌转移作用的孕甾烷生物碱衍生物及医药用途 |
| EP3313811A1 (en) | 2015-06-26 | 2018-05-02 | Aquinox Pharmaceuticals (Canada) Inc. | Crystalline solid forms of the acetate salt of (1s,3s,4r)-4-((3as,4r,5s,7as)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1h-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol |
| WO2017127753A1 (en) | 2016-01-20 | 2017-07-27 | Aquinox Pharmaceuticals (Canada) Inc. | Synthesis of a substituted indene derivative |
| WO2019195692A1 (en) * | 2018-04-06 | 2019-10-10 | Aquinox Pharmaceuticals (Canada) Inc. | Hexadecahydro-1h-cyclopenta[a]phenanthrene derivatives useful in treating pain and inflammation |
| JP2021526546A (ja) | 2018-04-06 | 2021-10-07 | アキノックス ファーマシューティカルス（カナダ）インク． | 疼痛及び炎症を治療するのに有用なインデン誘導体 |
| JP2021526545A (ja) | 2018-04-06 | 2021-10-07 | アキノックス ファーマシューティカルス（カナダ）インク． | 疼痛及び炎症を治療するのに有用なインデン誘導体 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3682983A (en) * | 1969-11-12 | 1972-08-08 | Klaus Prezewowsky | Preparation of {66 {11 {11 -17 ethinyl steroids |
| US4548922A (en) * | 1983-06-06 | 1985-10-22 | Beth Israel Hospital | Drug administration |
| ATE188036T1 (de) | 1990-01-18 | 2000-01-15 | Cura Nominees Pty Ltd | Glykoalkaloide |
| US5877185A (en) | 1991-10-22 | 1999-03-02 | Octamer, Inc. | Synergistic compositions useful as anti-tumor agents |
| CA2086221C (en) * | 1992-12-23 | 2003-07-15 | Raymond J. Andersen | Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agent |
| CA2157594A1 (en) * | 1993-03-10 | 1994-09-15 | Leah L. Frye | Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants |
| US5817632A (en) * | 1993-08-16 | 1998-10-06 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5856535A (en) * | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
| US6083532A (en) * | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
| WO1996036230A1 (en) | 1995-05-16 | 1996-11-21 | The Salk Institute For Biological Studies | Modulators for new members of the steroid/thyroid superfamily of receptors |
| US5874597A (en) | 1995-06-07 | 1999-02-23 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5847172A (en) * | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US6046185A (en) * | 1996-07-11 | 2000-04-04 | Inflazyme Pharmaceuticals Ltd. | 6,7-oxygenated steroids and uses related thereto |
| US6060465A (en) | 1997-02-06 | 2000-05-09 | Miljkovic; Dusan | Bile acids and their derivatives as glycoregulatory agents |
| ATE269086T1 (de) | 1998-03-06 | 2004-07-15 | Univ Brigham Young | Antibiotische steroidderivate |
| SK15692002A3 (sk) * | 2000-04-28 | 2003-11-04 | Inflazyme Pharmaceuticals Limited | 3-Amino-6,7-dioxygénované steroidy a s nimi súvisiace použitie |
-
2001
- 2001-04-30 SK SK1569-2002A patent/SK15692002A3/sk unknown
- 2001-04-30 BR BR0110419-5A patent/BR0110419A/pt not_active IP Right Cessation
- 2001-04-30 US US10/258,950 patent/US20040034216A1/en not_active Abandoned
- 2001-04-30 AU AU2001252084A patent/AU2001252084B2/en not_active Ceased
- 2001-04-30 DE DE60126597T patent/DE60126597T2/de not_active Expired - Lifetime
- 2001-04-30 RU RU2002131941/04A patent/RU2291873C2/ru not_active IP Right Cessation
- 2001-04-30 US US09/845,775 patent/US6635629B2/en not_active Expired - Fee Related
- 2001-04-30 JP JP2001580936A patent/JP2003531916A/ja active Pending
- 2001-04-30 NZ NZ522181A patent/NZ522181A/en unknown
- 2001-04-30 WO PCT/CA2001/000581 patent/WO2001083512A1/en not_active Ceased
- 2001-04-30 YU YU88102A patent/YU88102A/sh unknown
- 2001-04-30 CA CA002418748A patent/CA2418748A1/en not_active Abandoned
- 2001-04-30 EE EEP200200613A patent/EE200200613A/xx unknown
- 2001-04-30 AU AU5208401A patent/AU5208401A/xx active Pending
- 2001-04-30 ES ES01925262T patent/ES2282247T3/es not_active Expired - Lifetime
- 2001-04-30 CN CNB018101674A patent/CN1214039C/zh not_active Expired - Fee Related
- 2001-04-30 KR KR1020027014524A patent/KR20030045671A/ko not_active Ceased
- 2001-04-30 EP EP01925262A patent/EP1278763B1/en not_active Expired - Lifetime
- 2001-04-30 PT PT01925262T patent/PT1278763E/pt unknown
- 2001-04-30 PL PL01365798A patent/PL365798A1/xx not_active Application Discontinuation
- 2001-04-30 AP APAP/P/2002/002659A patent/AP1825A/en active
- 2001-04-30 HU HU0300908A patent/HUP0300908A2/hu unknown
- 2001-04-30 IL IL15244801A patent/IL152448A0/xx active IP Right Grant
- 2001-04-30 DZ DZ013355A patent/DZ3355A1/fr active
- 2001-04-30 OA OA1200200328A patent/OA12255A/en unknown
- 2001-04-30 MX MXPA02010645A patent/MXPA02010645A/es active IP Right Grant
- 2001-04-30 DK DK01925262T patent/DK1278763T3/da active
- 2001-04-30 AT AT01925262T patent/ATE353909T1/de not_active IP Right Cessation
- 2001-04-30 UA UA2002119460A patent/UA79229C2/uk unknown
- 2001-04-30 HR HR20020944A patent/HRP20020944A2/xx not_active Application Discontinuation
-
2002
- 2002-10-24 ZA ZA200208631A patent/ZA200208631B/en unknown
- 2002-10-24 NO NO20025106A patent/NO324873B1/no unknown
- 2002-10-24 IL IL152448A patent/IL152448A/en not_active IP Right Cessation
- 2002-11-19 BG BG107289A patent/BG107289A/bg unknown
- 2002-11-20 MA MA26916A patent/MA25808A1/fr unknown
- 2002-11-22 CO CO02106292A patent/CO5590904A2/es not_active Application Discontinuation
-
2003
- 2003-07-21 US US10/624,946 patent/US7112580B2/en not_active Expired - Fee Related
-
2006
- 2006-07-28 US US11/496,052 patent/US20070060553A1/en not_active Abandoned